<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        8-887-16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ALKERAN TABLETS 2 MG
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MELPHALAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        347.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="EXCELLA GmbH &amp; Co. KG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            EXCELLA GmbH & Co. KG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ASPEN PHARMA TRADING LIMITED (APTL)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01AA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1. What Alkeran is and what it is used for</strong><br />Alkeran tablets contain a medicine called melphalan which belongs to a group of medicines called cytotoxics (also called chemotherapy) and is used to treat certain types of cancer. It works by reducing the number of abnormal cells your body makes.</p><p>Alkeran tablet is used for:</p><ul><li>&nbsp;Multiple myeloma - a type of cancer that develops from cells in the bone marrow called plasma cells. Plasma cells help to fight infection and disease by producing antibodies.</li><li>&nbsp;Advanced cancer of the ovaries.</li><li>&nbsp;Advanced breast cancer.</li><li>&nbsp;Polycythaemia rubra vera - a type of blood cancer where the number of red cells in your blood increases due to uncontrolled red blood cell production in your body. This makes the blood thicken and causes blood clots, and may result in headaches, dizziness and shortness of breath.</li></ul><p>Ask your doctor if you would like more explanation about these diseases.<br />You must talk to a doctor if you do not feel better or if you feel worse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2. What you need to know before you take Alkeran</strong></p><p>Do not take Alkeran if:</p><ul><li>&nbsp;You are allergic to melphalan or any of the other ingredients of this medicine (listed in section 6).</li><li>&nbsp;You are breastfeeding.</li></ul><p>If you are not sure, talk to your doctor or pharmacist before taking Alkeran.<br />Warnings and precautions<br />Before you take Alkeran, tell your doctor or nurse if:</p><ul><li>&nbsp;you have had radiotherapy or chemotherapy, now or recently,</li><li>&nbsp;you have a kidney problem,</li><li>&nbsp;you are going to have a vaccination or were recently vaccinated. This is because some vaccines&nbsp;(like polio, measles, mumps and rubella) may give you an infection if you have them whilst you are taking melphalan,&nbsp;</li><li>you are using combined oral contraception (the pill). This is because of the increased risk of venous thromboembolism (a blood clot that forms in a vein and migrates to another location) in patients with multiple myeloma.</li></ul><p>Alkeran could increase the risk of developing other types of cancer (eg. secondary solid tumours) in a small number of patients, particularly when used in combination with lenalidomide, thalidomide and prednisone. Your doctor should carefully evaluate the benefits and risks when you are prescribed Alkeran.</p><p>If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking Alkeran.</p><p><strong>Other medicines and Alkeran</strong><br />Please tell your doctor if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription. This includes herbal medicines.<br />In particular, you must tell your doctor if you are taking any of the following:</p><ul><li>&nbsp;vaccines which contain live organisms (see Warnings and precautions),</li><li>&nbsp;nalidixic acid (an antibiotic used to treat urinary tract infections),</li><li>ciclosporin (used to prevent rejection of organs or tissues following a transplant or to treat certain skin conditions like psoriasis and eczema or to treat rheumatoid arthritis),</li><li>&nbsp;in children, busulfan (another chemotherapeutic drug used to treat certain type of cancers).</li></ul><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>Treatment with Alkeran is not recommended during pregnancy because it may cause permanent damage to a foetus. Do not take Alkeran if you are planning to have a baby. This applies to both men and women. Reliable contraceptive precautions must be taken to avoid pregnancy whilst you or your partner is taking these tablets.<br />If you are already pregnant, it is important to talk to your doctor before taking Alkeran.<br />Your doctor will consider the risks and benefits to you and your baby of taking Alkeran.</p><p>Do not breast-feed during treatment with Alkeran. Ask your doctor for advice.</p><p><strong>Fertility</strong><br />Melphalan can affect ovaries or sperm, which may cause infertility (inability to have a baby). In women, menstruation can stop (amenorrhoea) and in men, a complete lack of sperm can be observed (azoospermia). Due to the possibility of the lack of sperm as a result of melphalan treatment it is advised for men to have a consultation on sperm preservation before treatment. It is recommended that men who are receiving treatment with melphalan not father a child during treatment and up to 6 months afterwards.</p><p><strong>Driving and using machines</strong><br />Effects on the ability to drive and operate machinery in patients taking this medicine have not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3 How to take Alkeran</strong><br />Alkeran is an active cytotoxic agent for use under the direction of physicians experienced in the administration of such agents.</p><ul><li>Alkeran treatment must be initiated and monitored under the supervision of a physician experienced in the management of malignant disease.</li><li>&nbsp;Alkeran is a hazrdouse drug. Need caution when handling Alkeran to minimize risk of exposure.</li><li>Personal not taking Alkeran should not be exposed to it.</li><li>&nbsp;Tablets should be swallowed whole.</li><li>&nbsp;The tablets should not be broken, chewed or crushed.</li></ul><p>Always take Alkeran exactly as your doctor has told you. It is important to take your medicine at the right times. The label on your pack will tell you how many tablets to take and how often to take them. If the label doesn&rsquo;t say or if you are not sure, ask your doctor, nurse or pharmacist.</p><p>The dose of Alkeran depends on the type of your blood problem or cancer (see section 1).</p><p>Your doctor may also change your dose during your treatment, depending on your needs. The dose can sometimes be changed if you are an older person or have a kidney problem.<br />When you take Alkeran, your doctor will take regular blood tests. This is to check the number of cells in your blood. Your doctor may sometimes change your dose as a result.</p><p><em><strong>Thromboembolic events</strong></em><br />An increased risk of deep vein thrombosis (formation of a blood clot called thrombus within a deep vein, predominantly in the legs) and pulmonary embolism (a blockage of the lung&rsquo;s main artery or its branches by a blood clot that breaks off and travels to the lung).may occur when melphalan is used in combination with other medicines which can affect how your immune system works (such as lenalidomide/thalidomide) and others which can increase the benefits of the treatment with melphalan (such as prednisone/dexamethasone).</p><p>Your doctor will decide what measures should be taken after careful assessment of your underlying risk factors (such as smoking, increased blood pressure, high levels of lipids in the blood, history of thrombosis).</p><p>If you develop any signs or symptoms of thromboembolism (such as shortness of breath, chest pain, arm or leg swelling), tell your doctor immediately. If you experience any thromboembolic events, your doctor may decide to discontinue your treatment and to start a standard anticoagulation therapy. Your doctor will decide if you should restart melphalan in combination with lenalidomide and prednisone or thalidomide and prednisone or dexamethasone once the thromboembolic events have been managed.</p><p><em><strong>Neutropenia and thrombocytopenia</strong></em><br />An increase in the number of blood toxicities, such as neutropenia (decrease of the number of white blood cells, which may increase risk of having infections) and thrombocytopenia (low number of platelets, which may cause bleeding and bruising) have been seen when melphalan is used in combination with other medicines which can affect how your immune system works (such as lenalidomide/thalidomide) and others which can increase the benefits of the treatment with melphalan (such as prednisone/dexamethasone).</p><p><strong>Multiple myeloma</strong></p><ul><li>The usual dose is 0.15 mg per kilogram of your body weight each day for 4 days. This is repeated every 6 weeks.</li></ul><p><strong>Advanced ovarian adenocarcinoma</strong></p><ul><li>The usual dose is 0.2 mg per kilogram of your body weight each day for 5 days. This is repeated every 4 to 8 weeks.</li></ul><p><strong>Advanced breast carcinoma</strong></p><ul><li>&nbsp;The usual dose is 0.15 mg per kilogram of your body weight each day for 5 days. This is repeated every 6 weeks.</li></ul><p><strong>Polycythaemia rubra vera</strong></p><ul><li>&nbsp;Initially 6 to 10 mg each day for 5 to 7 days. The dose will then be reduced to 2 to 4 mg each day.</li></ul><p><strong>Use in Children</strong><br />Alkeran is only rarely indicated in children. Dosing guidelines for children are not available.</p><p><strong>If you take more Alkeran than you should</strong><br />If you take more Alkeran than you should, tell your doctor immediately or go to a hospital straight away. Take the medicine pack with you.</p><p><strong>If you forget to take Alkeran</strong><br />Tell your doctor.<strong> Do not take a double dose to make up for a forgotten dose.</strong></p><p><strong>If you stop taking Alkeran</strong><br />If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4. Possible side effects</strong></p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>If you get any of the following, talk to your specialist doctor or go to hospital straight away:</strong></p><ul><li>&nbsp;allergic reaction, the signs may include:</li></ul><p>&minus; a rash, lumps or hives on the skin<br />&minus; swollen face, eyelids or lips<br />&minus; sudden wheeziness and tightness of the chest<br />&minus; collapse (due to cardiac arrest)</p><ul><li>any signs of a high temperature or infection (sore throat, sore mouth or urinary problems). Treatment with Alkeran can cause a lowering of the white blood cell count. White blood cells fight infection, and when there are too few white blood cells, infections can occur</li><li>any <strong>unexpected </strong>bruising or bleeding or feeling extremely tired, dizzy or breathless, as this could mean that too few blood cells of a particular type are being produced</li><li>if you <strong>suddenly </strong>feel unwell (even with a normal temperature).</li><li>if you experience any of the symptoms/signs which may be related to a thromboembolic event (such as shortness of breath, chest pain, arm or leg swelling) especially if you are treated with Alkeran in combination with lenalidomide and prednisone or thalidomide and prednisone or dexamethasone.</li></ul><p>Talk to your doctor if you have any of the following side effects which may also happen with this medicine:</p><p><strong>Very common (affects more than 1 in 10 people)</strong></p><ul><li>a drop in the number of blood cells and platelets</li><li>&nbsp;feeling sick (nausea), being sick (vomiting) and diarrhoea &ndash;with high doses of Alkeran</li><li>&nbsp;mouth ulcers - with high doses of Alkeran</li><li>&nbsp;hair loss - with high doses of Alkeran</li></ul><p><strong>Common (affects less than 1 in 10 people)</strong></p><ul><li>&nbsp;hair loss - with usual doses of Alkeran</li><li>&nbsp;high levels of a chemical called urea in your blood - in people with kidney problems who are being treated for myeloma.</li></ul><p><strong>Rare (affects less than 1 in 1,000 people)</strong></p><ul><li>an illness where you have a low number of red blood cells as they are being destroyed prematurely - this can make you feel very tired, breathless and dizzy and can give you headaches or make your skin or eyes yellow</li><li>&nbsp;lung problems which may make you cough or wheeze and make it difficult to breathe</li><li>&nbsp;liver problems which may show up in your blood tests or cause jaundice (yellowing of the whites of eyes and skin)</li><li>mouth ulcers - with normal doses of Alkeran</li><li>&nbsp;skin rashes or itching skin</li></ul><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><ul><li>leukaemia - cancer of the blood</li><li>&nbsp;in women: your periods stopping (amenorrhoea)</li><li>&nbsp;in men: absence of sperm in the semen (azoospermia)</li><li>&nbsp;deep vein thrombosis and pulmonary embolism</li></ul><p>If any of the side effects become serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p>It is also possible that the use of Alkeran will increase the risk of developing another type of cancer called secondary acute leukaemia (cancer of the blood) in the future. Secondary acute leukaemia causes bone marrow (tissue in your bones that produces red and white blood cells) to produce large numbers of cells that do not work properly. Symptoms of this condition include tiredness, fever, infection and bruising. The condition may also be detected by a blood test which will show if there are large numbers of cells in your blood that are not working properly and too few blood cells that are working properly.</p><p>Tell your doctor as soon as possible if you have any of these symptoms. You may need to stop taking Alkeran, but only your doctor can tell you if that is the case.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5. How to store Alkeran</strong></p><ul><li>&nbsp;Keep this medicine out of the sight and reach of children.</li><li>&nbsp;Do not use this medicine after the expiry date, which is stated on the bottle label and the carton after &lsquo;Exp&rsquo;. This is printed as month; year and refers to the last date of the month.</li><li>&nbsp;Store in a refrigerator between 2 and 8&deg;C.</li><li>&nbsp;Alkeran is a hazardous drug, need caution when handling to minimize risk of exposure.</li><li>&nbsp;The tablets should not be divided, broken or crushed.</li><li>Transport and store medicine in the original container or blister.</li><li>&nbsp;For medication administration, use gloves and wash hands thoroughly before and after. If gloves are not worn, tip tablets and from their container/blister pack directly into a disposable medicine cup.</li><li>People who are not taking Alkeran should not be exposed to it.</li><li>Caution should be observed in handling broken or crushed tablets Avoid direct contact of the Alkeran with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water, rinse eyes thoroughly with sterile water, or plain water if sterile water is unavailable.</li><li>Pregnant should avoid exposure to Alkeran tablets.</li><li>Family members use gloves when handling laundry or cleaning within or around toilets.</li><li>Close the lid before flushing the toilet and flush twice after each use by patient, for 48 hours after receiving chemotherapy. If available, use separate bathroom from family members.</li><li>&nbsp;Conduct double washing of linens and wash them separately from other family laundry.</li><li>If your doctor tells you to stop taking the medication, or if it expired. Do not throw away via wastewater or household waste. Ask your pharmacist how to throw away medicine you no longer use, or return it to your pharmacist, who will destroy them according to disposal of dangerous substance guidelines.</li><li>These measures will help protect environment.</li><li>Only keep the medicine if your doctor tells you to.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Alkeran contains</strong><br />The active substance is melphalan. Each Alkeran tablet contains 2 mg of melphalan. The other ingredients are microcrystalline cellulose, crospovidone, colloidal anhydrous silica, magnesium stearate, hypromellose, titanium dioxide (E171) and macrogol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Alkeran looks like and contents of the pack
Alkeran tablets are white to off-white film-coated, round, biconvex tablets engraved with ‘GX EH3’ on one side and ‘A’ on the other. Your Alkeran tablets are in bottles of 25 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer</strong></p><p><strong>Marketing Authorisation holder:</strong><br />Aspen Pharma Trading Limited 3016 Lake Drive,<br />Citywest Business Campus, Dublin 24, Ireland<br />&nbsp;</p><p><strong>Manufacturer:</strong><br />EXCELLA GmbH &amp; Co. KG,<br />N&uuml;rnberger Strasse 12, 90537 Feucht, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in {February/2022}, Version number {4}.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>&nbsp; 1 . ما هو ألكيران و ما هي دواعي استخدامه</strong><br />تحتوي أقراص ألكيران على دواء يسمى ميلفالان و الذي ينتمي إلى مجموعة أدوية تسمى بالسيتوتوكسين (الأدوية السامة للخلايا أو العلاج الكيماوي) و تستعمل لعلاج بعض أنواع السرطان عن طريق خفض عدد الخلايا الغير طبيعية التي ينتجها الجسم.</p><p>تستعمل أقراص ألكيران في :</p><ul><li><strong>&nbsp;الورم النخاعي المتعدد -</strong> نوع من السرطانات ينتج من خلايا نخاع العظم التي تسمى خلايا البلازما. تساهم خلايا البلازما في محاربة العدوى و الأمراض بإنتاج الأجسام المضادة .</li><li>&nbsp;<strong>سرطان المبيضين </strong>المتقدم</li><li><strong>&nbsp;سرطان الثدي</strong> المتقدم</li></ul><p><strong>كثرة الحمر الحقيقية</strong><br />- نوع من سرطان الدم حيث يزيد عدد خلايا الدم الحمراء بسبب إنتاج خلايا الدم غير المنضبط في الجسم مما يجعل الدم غليظ كما يسبب جلطات بالدم و قد يؤدي إلى حدوث الصداع و الدوخة و ضيق التنفس.</p><p>اسأل طبيبك إذا اردت معلومات أكثر عن هذه الأمراض.<br />يجب عليك إخبار الطبيب إذا لم تتحسن حالتك أو إذا ساءت الحالة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>2. ما الذي تحتاج إلى معرفته قبل البدء في تنأول ألكيران<br />لا تأخذ ألكيران إذا:</strong></p><ul><li dir="rtl">كانت لديك حساسية من ميلفالان أو من احد المكونات الاخرى لهذا الدواء (المذكورة بالفقرة 6) .</li><li>كنت ترضعين.</li></ul><p>إذا لم تكن متأكدا، تحدث إلى طبيبك أو الصيدلي قبل تناول ألكيرا ن.</p><p><strong>التحذيرات و الاحتياطات</strong><br />قبل تناول ألكيران، اخبر طبيبك أو الممرض إذا :</p><ul><li>&nbsp;خضعت للعلاج بالإشعاع أو الكيماوي الآن أو منذ وقت قريب،</li><li>&nbsp;لديك مشاكل بالكلى،</li><li>&nbsp;كنت مقبلا على تناول لقاحا أو تناولت لقاحا مؤخرا. هذا لان بعض أنواع اللقاحات (مثل شلل الأطفال والحصبة والتهاب الغدة النكافية والحصبة الألمانية) قد تصيبك بعدوى إذا تناولت أي منهم بينما كنت تتناول ميلفالان ،</li><li>&nbsp;إذا كنت تستعمل موانع الحمل المركبة عن طريق الفم (الأقراص). و هذا لارتفاع خطر الإصابة بالجلطات الدموية الوريدية (الجلطة الدموية التي تتشكل في الوريد وتهاجر إلى مكان آخر) عند المرضى الذين يعانون من الورم النخاعي المتعدد.</li></ul><p>قد يزيد ألكيران من خطر الإصابة بأنواع سرطانية اخرى (مثل أورام صلبة ثانوية) في عدد قليل من المرضى، خصوصا عند استعماله مع ليناليدوميد، ثاليدوميد و بريدنيزون. على طبيبك تقييم الفوائد و المخاطر عند و وصفه ألكيران .<br />إذا لم تكن متأكدا أن أي مما سبق ينطبق عليك، تحدث إلى طبيبك أو الصيدلي قبل تناول ألكيران.</p><p><strong>الأدوية الأخرى و ألكيران</strong><br />يرجى إخبار طبيبك إذا كنت تتناول أو تناولت أو قد تتناول أدوية أخرى، بما في ذلك الأدوية التي تصرف بدون وصفة طبية و التي تشمل أيضا الأدوية العشبية.<br />على وجه الخصوص، عليك إخبار طبيبك إذا كنت تتناول أي من الآتي:</p><ul><li>&nbsp;اللقاحات التي تحتوي أجساما حية (راجع التحذيرات و الاحتياطات)،</li><li>&nbsp;حمض الناليديكسيك (مضاد حيوي لعلاج التهابات الجهاز البولي)،</li><li>&nbsp;سيكلوسبورين (تستعمل لمنع رفض الجسم للأعضاء أو الأنسجة المزروعة أو لعلاج بعض أمراض الجلد مثل الصدفية والأكزيما أو لعلاج التهاب المفاصل الروماتويدي)،</li><li>في الأطفال، بوسولفان (علاج كيماوي آخر يستخدم لعلاج بعض أنواع السرطانات).</li></ul><p><strong>الحمل، الرضاعة و الخصوبة</strong><br /><strong>الحمل و الرضاعة</strong><br />إذا كنت حاملا أو ترضعين أو تظنين أنك حامل أو تخططين للحمل ، استشيري طبيبك قبل تناول هذا الدواء .</p><p>لا ينصح العلاج بالألكيران خلال الحمل لأنه قد يحدث ضرر دائم للجنين. لا تأخذ ألكيران إذا كنت تخططين للحمل.<br />ينطبق هذا على الرجل و المرأة . يجب اعتماد موانع الحمل الفعالة لتجنب الحمل أثناء تناولك أنت أو شريكك هذه الأقراص .</p><p>إذا كنت حاملا بالفعل، من المهم التحدث إلى طبيبك قبل تناول ألكيران .<br />طبيبك سوف يقيم المخاطر و الفوائد لك و للطفل من تناول ألكيران .</p><p>لا ترضعي الطفل خلال العلاج بألكيران. استشيري طبيبك.</p><p><strong>الخصوبة</strong><br />قد يؤثر ميلفالان على المبيضين و الحيوانات المنوية، و الذي قد يسبب العقم (عدم القدرة على الانجاب). عند المرأة، قد تتوقف الدورة الشهرية (انقطاع الطمث) أما عند الرجل، يمكن حدوث انعدام كامل للحيوانات المنوية (فقد النطاف). بسبب امكانية حدوث انعدام النطاف كنتيجة للعلاج بميافالان ، ينصح المريض بالاستفسار عن بنوك الحيوانات المنوية قبل العلاج. ينصح الرجال الذين يتناولون ميلفالان بعدم محاولة الإنجاب خلال العلاج و حتى 6 اشهر بعد توقف العلاج.</p><p><strong>القيادة و استعمال الآلات</strong><br />لم تدرس بعد الآثار الناجمة عن استعمال هذا الدواء على القدرة على القيادة و استعمال الآلات</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>3. كيف تتناول ألكيران</strong><br />إن ألكيران دواء سام للخلايا فعال للاستعمال تحت إشراف أطباء خبراء في اعطاء هذا النوع من الأدوية .</p><ul><li>&nbsp;يجب بدء العلاج بألكيران ومراقبته تحت إشراف طبيب خبير في إدارة الأمراض الخبيثة .</li><li>&nbsp;ألكيران دواء خطير. ينبغي توخي الحذر عند التعامل مع ألكيران للحد من مخاطر التعرض.</li><li>&nbsp;الشخص الذي لا يتناول ألكيران يجب ألا يتعرض له .</li><li>&nbsp;يجب ابتلاع الأقراص كاملة .</li><li>&nbsp;يجب ألا تُكسر الأقراص، أو تمضغ أو تسحق .</li></ul><p>يؤخذ ألكيران دائما كما وصفه طبيبك لك. من المهم تناول العلاج في الأوقات المحددة. ملصق العبوة سيخبرك عن عدد الأقراص التي عليك تناولها و عدد مرات التناول. إذا لم يحدد الملصق ذلك أو إن لم تكن متأكدا، اسأل طبيبك، الممرض أو الصيدلي .</p><p>تعتمد جرعة ألكيران على نوع مشاكل الدم أو السرطان (انظر القسم 1 ).</p><p>قد يغير طبيبك جرعتك خلال فترة العلاج و حسب حاجتك. قد تتغير الجرعة احيانا إذا كنت شخصا مسنا أو لديك قصور كلوي . أثناء تناولك لألكيران، سيجري لك طبيبك تحاليل للدم دورية. هذا لحساب عدد الخلايا بالدم. كنتيجة لذلك قد يغير طبيبك الجرعة أحيانا.</p><p><br /><strong>الانسداد التجلطي</strong><br />قد يزيد خطر الإصابة بالتخثر في الأوردة العميقة (تشكيل جلطة دموية تسمى بخثرة داخل وريد عميق، غالبا ما تكون في الساقين)و انسداد رئوي (انسداد في الوريد الرئيسي بالرئة أو بأحد فروعه بجلطة دموية و التي قد تنفصل و تهاجر إلى الرئة) أثناء تناول ميلفالان مع أدوية أخرى والتي قد تؤثر على وظيفة جهازك المناعي(مثل ليناليدوميد/ ثاليدوميد) أو أخرى يمكن أن تزيد من فوائد العلاج بميلفالان (مثل بريدنيزون/ ديكساميثازون).</p><p>سيقرر طبيبك التدابير التي سيتخذها بعد تقييم دقيق لعوامل الخطر الأساسية الخاصة بك (مثل التدخين وارتفاع ضغط الدم وارتفاع نسبة الدهون بالدم و سابقة تخثر الدم).</p><p>إذا ظهرت عليك احد علامات أو أعراض الانسداد التجلطي (مثل ضيق التنفس أوألم الصدر أو تورم الذراع أو الرجل)، اخبر طبيبك فورا. إذا عانيت من أي نوع من أنواع الانسداد التجلطي، قد يقرر طبيبك ايقاف العلاج و البدء بعلاج مضاد لتخثر الدم .</p><p>سيقرر طبيبك ما إذا كنت ستتناول ميلفالان مع ليناليدوميد و بريدنيزون أو تاليدوميد و بريدنيزون أو ديكساميثازون من جديد بعد التحكم بالانسداد التجلطي .</p><p><strong>قلة العدلات و الصفيحات الدموية</strong><br />لقد لوحظ ارتفاع نسبة سميات الدم، مثل قلة العدلات (انخفاض عدد كريات الدم البيضاء ما قد يرفع خطر العدوى) و قلة الصفيحات الدموية (قلة عدد الصفائح الدموية، مما قد يسبب النزيف والكدمات) عند استعمال ميلفالان مع أدوية اخرى و التي قد تؤثر على وظيفة جهازك المناعي(مثل ليناليدوميد/تاليدوميد) و اخرى يمكن أن تزيد من فوائد العلاج مع ميلفالان(مثل بريدنيزون/ديكساميثازون) .</p><p><strong>الورم النخاعي المتعدد</strong></p><ul><li>&nbsp;الجرعة المعتادة هي 0.15 ملجم لكل كيلوجرام من وزن الجسم يوميا ولمدة 4 أيام. يتكرر كل 6 أسابيع .</li></ul><p><strong>سرطان الغدة الفوق مبيضية المتقدم</strong></p><ul><li>&nbsp;الجرعة المعتادة هي 0.2 ملجم لكل كيلوجرام من وزن الجسم يوميا ولمدة 5 أيام. يتكرر كل 4 إلى 8 أسابيع .</li></ul><p><strong>سرطان الثدي المتقدم</strong></p><ul><li>&nbsp;الجرعة المعتادة هي 0.15 ملجم لكل كيلوغرام من وزن الجسم يوميا ولمدة 5 أيام. يتكرر كل 6 أسابيع .</li></ul><p><strong>كثرة الحمر في الدم</strong></p><ul><li>&nbsp;الجرعة الأولية 6 إلى 10 ملجم يوميا خلال 5 إلى 7 أيام .</li></ul><p>ستنخفض الجرعة إلى 2 إلى 4 ملجم كل يوم .</p><p><strong>الاستعمال في الأطفال</strong><br />نادرا ما يستعمل ألكيران عند الأطفال. لا تتوفر أي معلومات عن تحديد الجرعات في الأطفال .</p><p><strong>إذا تناولت ألكيران أكثر مما ينبغي</strong><br />إذا تناولت ألكيران أكثر مما ينبغي، اخبر طبيبك فورا أو اذهب مباشرة إلى المستشفى ومعك عبوة الدواء .</p><p><strong>إذا نسيت تناول ألكيران</strong><br />اخبر طبيبك. لا تأخذ ضعف الجرعة لتعويض تلك التي نسيتها .</p><p><strong>إذا توقفت عن تناول ألكيران</strong><br />إذا كانت لديك أسئلة أخرى عن استعمال هذا الدواء، اسأل طبيبك أو الممرض .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>4. </strong><strong>الآثار الجانبية الممكنة</strong></p><p dir="RTL">مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثارا جانبية، و التي لا تحدث عند كل المرضى.</p><p dir="RTL"><strong>إذا ظهر لديك أي من الآتي، تحدث إلى طبيبك المختص أو اذهب إلى المستشفى مباشرة</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية، وتشمل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، تكتلات فوق الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه، الجفون أو الشفاه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصفير وضيق الصدر المفاجئين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التدهور (بسبب سكتة قلبية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي أعراض لارتفاع درجة الحرارة أو التهاب (التهاب الحلق، التهاب الفم أو مشاكل في البول). قد يسبب العلاج بألكيران انخفاض في عدد خلايا الدم البيضاء و التي تحارب الالتهاب وعندما تنخفض بشدة، يمكن أن تحدث العدوى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي كدمات أو نزيف أو الشعور بالتعب الشديد <strong>الغير المتوقعين</strong> أو بالدوار أو ضيق التنفس الغير متوقعين أيضا، وهذا قد يعني أن عدد قليل جدا من خلايا الدم من نوع معين يتم إنتاجها.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أحسست فجأة بتوعك (حتى بدرجة حرارة طبيعية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا شعرت بأحد الأعراض/العلامات والتي قد تكون مرتبطة بالانسداد التجلطي (كضيق في التنفس، ألم بالصدر، تورم بالذراع أو الرجل) خاصة إذا كان العلاج بألكيران متزامن مع ليناليدوميد و بريدنيزون أو ثاليدوميد و بريدنيزون أو ديكساميثازون.</p><p dir="RTL">أخبر طبيبك إذا ظهرت لديك الآثار الجانبية التالية والتي قد تحدث مع هذا الدواء أيضاً:</p><p dir="RTL"><strong>متكررة جدا (تصيب أكثر من 1 من كل 10 أشخاص)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انهيار في عدد خلايا الدم و الصفائح الدموية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بالإعياء(غثيان)، التقيؤ والإسهال - مع جرعات مرتفعة من ألكيران</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرحات بالفم - مع جرعات مرتفعة من ألكيران</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سقوط الشعر - مع جرعات مرتفعة من ألكيران</p><p dir="RTL"><strong>متكررة ( تصيب أقل من 1 من كل 10 أشخاص</strong><strong>)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سقوط الشعر - مع جرعة اعتيادية من ألكيران</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نسب مرتفعة من مادة كيميائية في الدم تسمى اليوريا &ndash; عند الأشخاص ذوي القصور الكلوي ممن يعالجون من سرطان النخاع الشوكي.</p><p dir="RTL"><strong>نادرة (تصيب أقل من 1 من كل 1000 شخص</strong><strong>)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم الانحلالي و هو مرض حيث تنخفض عدد كريات الدم الحمراء بسبب تدميرها قبل الأوان - ما يشعرك بالتعب الشديد، ضيق التنفس و الدوار و الم بالرأس أو اصفرار الجلد أو العيون</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل الرئة والتي قد تجعلك تسعل أو تتنفس بالصفير وتسبب صعوبة التنفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالكبد ما يظهر جلياً من خلال تحاليل الدم أو حدوث اليرقان (اصفرار ابيض العينين و الجلد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرحات بالفم - مع جرعات اعتيادية من ألكيران</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي أو الحكة الجلدية</p><p dir="RTL"><strong>غير معروفة (لا يمكن تقييم ترددها من البيانات المتوفرة</strong><strong>)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوكيميا - سرطان الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند المرأة: توقف الدورة الشهرية (انقطاع الطمث)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند الرجل: انعدام الحيوانات المنوية في المني (فقد النطاف)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخثر وعائي عميق وانسداد رئوي</p><p dir="RTL">إذا اشتدت أي من الآثار الجانبية، أو لاحظت أي اثر جانبي غير مذكور بهذه النشرة، اخبر طبيبك أو الصيدلي.</p><p dir="RTL">من الممكن أيضا أن يؤدي تناول ألكيران إلى ارتفاع خطر الإصابة بنوع أخر من السرطان يسمى لوكيميا حادة ثانوية (سرطان الدم) في المستقبل. تحث اللوكيميا الحادة الثانوية النخاع العظمي (نسيج بالعظم ينتج خلايا الدم الحمراء و البيضاء) على انتاج عدد كبير من الخلايا التي لا تعمل بطريقة صحيحه. تشمل اعراض هذه الحالة التعب و الحمى و الالتهاب و الكدمات. يمكن تشخيص الحالة بتحاليل طبية للدم و التي ستظهر وجود عدد كبير من الخلايا التي لا تعمل بصورة صحيحة مقارنة بعدد قليل من الخلايا التي تعمل بصورة صحيحة.</p><p dir="RTL">اخبر طبيبك فورا إذا كانت لديك احد الأعراض المذكورة. قد تضطر إلى التوقف عن تناول ألكيران، و هذا يحدده الطبيب فقط.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>5. كيفية تخزين ألكيران</strong><br />&bull; يحفظ هذا الدواء بعيدا عن رؤية ومتناول الأطفال .<br />&bull; لا يستعمل هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على ملصق الزجاجة و العبوة الخارجية بعد&nbsp; &lt;EXP&gt;&nbsp;. تاريخ انتهاء الصلاحية مطبوع بالشهر و السنة و يمثل آخر يوم من الشهر .<br />&bull; يحفظ بالثلاجة بين 2 و 8 درجة مئوية .<br />&bull; ألكيران دواء خطير، وينبغي توخي الحذر عند التعامل معه للحد من مخاطر التعرض .<br />&bull; يجب ألا تُقسم الأقراص، أو تُكسر أو تُسحق.<br />&bull; يُنقل الدواء ويُخزن في الشريط أو الحاوية الأصلية .<br />&bull; لتقديم الدواء، تُستخدم القفازات وتُغسل اليدين جيداً قبل تقديم الدواء وبعده. في حالة عدم ارتداء القفازات، تقلب الأقراص من عبوتها/ الشريط مباشرة في كوب طبي يمكن التخلص منه.<br />&bull; الأشخاص الذين لا يتناولون ألكيران يجب ألا يتعرضوا له .<br />&bull; يجب توخي الحذر عند التعامل مع أقراص مكسورة أو مسحوقة. تجنب التلامس المباشر لألكيران مع الجلد أو الأغشية المخاطية. في حالة حدوث التلامس، يُغسل موضع التلامس جيداً بالماء والصابون، وتُشطف العينين جيداً بماء معقم، أو ماء عادي في حالة عدم توفر الماء المعقم.<br />&bull; ينبغي على السيدات الحوامل تجنب التعرض لأقراص ألكيران.<br />&bull; يجب على أفراد الأسرة استخدام القفازات عند التعامل مع الغسيل أو التنظيف داخل المراحيض أو حولها .<br />&bull; أغلق الغطاء قبل شطف المرحاض بالدفق واشطفه مرتين بعد كل استخدام من قبل المريض، وذلك لمدة 48 ساعة بعد تلقي العلاج الكيميائي. عند التوفر، استخدم حماما منفصلاً عن الحمام الذي يستخدمه أفرا د الأسرة .<br />&bull; يجب غسل البياضات غسلاً مزدوجا وتغسل بشكل منفصل عن غسيل الأسرة الآخر .<br />&bull; إذا أخبرك الطبيب بالتوقف عن تناول الدواء، أو انتهت صلاحيته. لا تتخلص من الدواء في ماء الصرف الصحي أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها، أو أعدها إلى الصيدلي الذي سيقوم بإتلافها وفقا لإرشادات التخلص من المواد الخطرة.<br />&bull; ستساعد هذه الإجراءات في الحفاظ على البيئة.<br />&bull; احتفظ بالدواء فقط إذا أخبرك طبيبك بذلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما يحتويه ألكيران</strong></p><p dir="RTL">المادة الفعالة هي ميلفالان. كل قرص من ألكيران يحتوي على2 ملجم من ميلفالان. المكونات الأخرى هي ميكروكريستالين سيليلوز، كروسبوفيدون، كولوويدال سيليكا لامائي، ستيارات المغنيسيوم، هيبروميلوز،ثاني أكسيد التيتانيوم (E171) وماكروجول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل ألكيران ومحتويات العبوة</strong></p><p dir="RTL">أقراص ألكيران بيضاء مائلة البياض مغلفة، دائرية ومحدبة الوجهين، منقوشGX EH3 &nbsp;على وجه واحد &lt;A&gt; بالوجه الأخر. أقراص ألكيران تأتي بزجاجات بها 25 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك حق التسويق والمصنع</strong></p><p dir="RTL"><strong>مالك حق التسويق:</strong><br />أسبن فارما تريدينج ليميتد<br />3016 ليك درايف<br />سيتي ويست بيزنس كامبوس<br />دبلن 24<br />إيرلندا</p><p dir="RTL"><strong>الشركة المصنعة:</strong><br />إكسيلا وشركاؤه المحدودة<br />طريق نورنبرجر 90537،12<br />فويشت<br />ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في{مارس /2022}، رقم النسخة {4}
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alkeran 2 mg Film-coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 2 mg melphalan.
For a full list of excipients see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet

White to off white, film-coated, round, biconvex tablets engraved 'GXEH3' on one side and an 'A' on the other.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Melphalan tablets are indicated in the treatment of:<br />&minus; multiple myeloma;<br />&minus; advanced ovarian adenocarcinoma.</p><p>Melphalan tablets may be used in the treatment of:<br />&minus; breast carcinoma: melphalan either alone or in combination with other drugs has a significant therapeutic effect in a proportion of patients suffering from advanced breast carcinoma.</p><p>Alkeran Tablets may be used in the management of polycythaemia rubra vera.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>Alkeran is a cytotoxic drug which falls into the general class of alkylating agents. It should be prescribed, initiated and monitored under the supervision of physicians experienced in the management of malignant disease with such agents.</p><p>Since melphalan is myelosuppressive, frequent blood counts are essential during therapy and the dosage should be delayed or adjusted if necessary (see section 4.4).</p><p><em><u>Thromboembolic events</u></em></p><p>Melphalan in combination with lenalidomide and prednisone or thalidomide and prednisone or dexamethasone is associated with an increased risk of venous thromboembolism (predominantly deep vein thrombosis and pulmonary embolism). Thromboprophylaxis should be administered for at least the first 5 months of treatment especially in patients with additional thrombotic risk factors. The decision to take antithrombotic prophylactic measures should be made after careful assessment of an individual patient&#39;s underlying risk factors (see sections 4.4 and 4.8).</p><p>If the patient experiences any thromboembolic events, treatment must be discontinued and standard anticoagulation therapy started. Once the patient has been stabilised on the anticoagulation treatment and any complications of the thromboembolic event have been managed, melphalan in combination with lenalidomide and prednisone or thalidomide and prednisone or dexamethasone may be restarted at the original dose dependent upon a benefit-risk assessment. The patient should continue anticoagulation therapy during the course of melphalan treatment.</p><p><u>Posology</u></p><p><em>Multiple myeloma</em></p><p>A typical oral dosage schedule is 0.15 mg/kg bodyweight/day in divided doses for 4 days repeated at intervals of six weeks. Numerous regimens have, however, been used and the scientific literature should be consulted for details.</p><p>The administration of oral Alkeran and prednisone may be more effective than Alkeran alone. The combination is usually given on an intermittent basis.</p><p>Prolonging treatment beyond one year in responders does not appear to improve results.</p><p><em>Advanced ovarian adenocarcinoma</em></p><p>A typical regimen is 0.2 mg/kg bodyweight/day given orally in divided doses for 5 days. This is repeated every 4 to 8 weeks, or as soon as the bone marrow has recovered.</p><p><em>Carcinoma of the breast</em></p><p>Alkeran has been given orally at a dose of 0.15 mg/kg bodyweight or 6 mg/m2 body surface area/day for 5 days and repeated every 6 weeks. The dose was decreased if bone marrow toxicity was observed.</p><p><em>Polycythaemia rubra vera</em></p><p>For remission induction doses of 6 to l0 mg daily for 5 to 7 days have been used, after which 2 to 4 mg daily were given until satisfactory disease control was achieved. A dose of 2 to 6 mg once per week has been used for maintenance therapy. In view of the possibility of severe myelosuppression if Alkeran is given on a continuous basis, it is essential that frequent blood counts are taken throughout therapy, with dosage adjustment or breaks in treatment, as appropriate, to maintain careful haematological control.</p><p><em>Paediatric population</em></p><p>Alkeran is only rarely indicated in the paediatric population and absolute dosage guidelines cannot be provided.</p><p><em>Elderly population</em></p><p>Although Alkeran is frequently used at conventional dosage in the older people, there is no specific information available relating to its administration to this patient sub-group. However, caution should be taken where there is renal impairment.</p><p><em>Renal impairment</em></p><p>Alkeran clearance, though variable, may be decreased in renal impairment (see section 4.4).</p><p>Currently available pharmacokinetic data do not justify an absolute recommendation on dosage reduction when administering Alkeran Tablets to patients with renal impairment, but it may be prudent to use a reduced dosage initially until tolerance is established.</p><p><u>Method of administration</u></p><p>Oral administration in adults: The absorption of Alkeran after oral administration is variable. Dosage may need to be cautiously increased until myelosuppression is seen, in order to ensure that potentially therapeutic levels have been reached.</p><ul><li>&nbsp;Alkeran is a cytotoxic agent. Follow applicable special handling and disposal procedures (see section 6.6).</li><li>&nbsp; Tablets should be swallowed whole.</li><li>The tablets should not be broken or crushed, if possible. This might produce powder that can contaminate workplace surfaces.</li><li>&nbsp; If tablet must be cut or crushed, this should be done by a professional trained personal experienced in safe handling of hazardous drugs using an appropriate equipment and safety procedures.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Lactation.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ALKERAN IS AN ACTIVE CYTOTOXIC AGENT FOR USE UNDER THE DIRECTION OF PHYSICIANS EXPERIENCED IN THE ADMINISTRATION OF SUCH AGENTS.</p><p>Immunisation using a live organism vaccine has the potential to cause infection in immunocompromised individuals. Therefore, immunisations with live organism vaccines are not recommended.</p><p><u>Monitoring</u><br />Bone marrow depression, with leucopenia and thrombocytopenia, is the main side effect. The time of maximum depression is variable, and careful attention should be paid to the monitoring of blood counts to avoid the possibility of excessive myelosuppression and the risk of irreversible bone marrow aplasia.</p><p>Blood counts may continue to fall after treatment is stopped so at the first sign of an abnormally large fall in leukocyte or platelet counts treatment should be temporarily interrupted.</p><p>Alkeran should be used with caution in patients who have undergone recent radiotherapy or chemotherapy in view of increased bone marrow toxicity.</p><p><u>Venous thromboembolic events</u><br />Patients treated with melphalan in combination with lenalidomide and prednisone or thalidomide and prednisone or dexamethasone, have an increased risk of deep vein thrombosis and pulmonary embolism (see section 4.8). The risk appears to be greatest during the first 5 months of therapy, especially in patients with additional thrombotic risk factors (e.g. smoking, hypertension, hyperlipidaemia and history of thrombosis). These patients should be closely monitored and actions to minimize all modifiable risk factors should be undertaken. Thromboprophylaxis and dosing/anticoagulation therapy recommendations are provided in section 4.2.</p><p>Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Patients should be instructed to seek medical care if they develop symptoms such as shortness of breath, chest pain, arm or leg swelling. If a patient experiences any thromboembolic events, discontinue the treatment immediately and initiate the standard anticoagulation therapy. Once the patient has been stabilised on the anticoagulation treatment and any complications of the thromboembolic event have been managed, melphalan in combination with lenalidomide and prednisone or thalidomide and prednisone or dexamethasone may be restarted at the original dose dependent upon a benefit-risk assessment. The patient should continue anticoagulation therapy throughout the course of treatment.</p><p><u>Neutropenia and thrombocytopenia</u><br />Increased rate of haematological toxicities, particularly, neutropenia and thrombocytopenia, was observed in newly diagnosed elderly multiple myeloma in patients treated with melphalan in combination with lenalidomide and prednisone or thalidomide and prednisone or dexamethasone. Patients and physicians are advised to be observant for signs and symptoms of bleeding, including petechiae and epistaxes, especially in patients receiving combination drug regimens described (section 4.8).</p><p><u>Mutagenicity</u><br />Melphalan has been shown to be mutagenic and carcinogenic in animals and chromosome aberrations have been observed in patients being treated with the drug. Melphalan has also been shown to be carcinogenic in animals (section 5.3), and the possibility of a similar effect should be borne in mind when designing the long-term management of the patient.</p><p><u>Carcinogenicity (Second primary malignancy)</u><br />Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)</p><p>Alkeran, in common with other alkylating agents has been reported to be leukaemogenic, especially in older patients after long combination therapy and radiotherapy.</p><p>There have been reports of acute leukaemia occurring after melphalan treatment for diseases such as amyloidosis, malignant melanoma, multiple myeloma, macroglobulinaemia, cold agglutinin syndrome and there has been a significant increase in patients with ovarian cancer.</p><p>A comparison of patients with ovarian cancer who received alkylating agents with those who did not showed that the use of alkylating agents, including melphalan, significantly increased the incidence of acute leukaemia.</p><p>Before the start of the treatment, the leukaemogenic risk (AML and MDS) must be balanced against the potential therapeutic benefit, especially if the use of melphalan in combination with thalidomide or lenalidomide and prednisone is considered, as it has been shown that these combinations may increase the leukaemogenic risk. Before, during and after treatment doctors must therefore examine the patient at all times by usual measurements to ensure the early detection of cancer and initiate treatment if necessary.</p><p>Solid tumours<br />Use of alkylating agents has been linked with the development of second primary malignancy (SPM). In particular, melphalan in combination with lenalidomide and prednisone and, to a lesser extent, thalidomide and prednisone has been associated with the increased risk of solid SPM in elderly newly diagnosed multiple myeloma patients.</p><p>Patient characteristics (e.g. age, ethnicity), primary indication and treatment modalities (e.g. radiation therapy, transplantation), as well as environmental risk factors (e.g., tobacco use) should be evaluated prior to melphalan administration.</p><p><u>Contraception</u><br />Due to an increased risk of venous thromboembolism in patients undergoing treatment with melphalan in combination with lenalidomide and prednisone or in combination with thalidomide and prednisone or dexamethasone, combined oral contraceptive pills are not recommended. If a patient is currently&nbsp;using combined oral contraception, she should switch to another reliable contraceptive method (i.e. ovulation inhibitory progesterone-only pills such as desogestrel, barrier method, etc). The risk of venous thromboembolism continues for 4&minus;6 weeks after discontinuing combined oral contraception.</p><p><u>Renal impairment</u><br />Alkeran clearance may be reduced in patients with renal impairment, who may also have uraemic bone marrow suppression. Dose reduction may therefore be necessary (see section 4.2), and these patients should be closely observed.</p><p>Temporary significant elevation of the blood urea has been seen in the early stages of melphalan therapy in myeloma patients with renal damage.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Live organism vaccines</u><br />Vaccinations with live organism vaccines are not recommended in immunocompromised individuals (see section 4.4).</p><p><u>Nalidixic acid</u><br />Nalidixic acid together with high-dose intravenous melphalan has caused deaths in the paediatric population due to haemorrhagic enterocolitis.</p><p><u>Busulfan</u><br />In paediatric population, for the Busulfan-Melphalan regimen it has been reported that the administration of melphalan less than 24 hours after the last oral busulfan administration may influence the development of toxicities.</p><p><u>Cyclosporin</u><br />Impaired renal function has been described in bone marrow transplant patients who were pre-conditioned with high dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u><br />There are no data from the use of melphalan in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). In view of its mutagenic properties and structural similarity to known teratogenic compounds, it is possible that melphalan could cause congenital defects in the offspring of patients treated with the drug.</p><p>Alkeran should be not be used during pregnancy and particularly during the first trimester, unless considered absolutely essential by the physician. In any individual case the potential hazard to the foetus must be balanced against the expected benefit to the mother.</p><p>As with all cytotoxic chemotherapy, adequate contraceptive precautions should be practised when either partner is receiving Alkeran.</p><p><u>Breast-feeding</u><br />Mothers receiving Alkeran should not breastfeed (see section 4.3).</p><p><u>Fertility</u></p><p>Alkeran causes suppression of ovarian function in premenopausal women resulting in amenorrhoea in a significant number of patients.</p><p>There is evidence from some animal studies that Alkeran can have an adverse effect on spermatogenesis (see section 5.3). Therefore, it is possible that Alkeran may cause temporary or permanent sterility in male patients.</p><p>It is recommended that men who are receiving treatment with melphalan not father a child during treatment and up to 6 months afterwards and that they have a consultation on sperm preservation before treatment due to the possibility of irreversible infertility as a result of melphalan treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects on the ability to drive and operate machinery in patients taking this medicine have not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For this product there is no modern clinical documentation which can be used as support for determining the frequency of undesirable effects. Undesirable effects may vary in their incidence depending on the indication and dose received and also when given in combination with other therapeutic agents.</p><p>The following convention has been utilised for the classification of frequency: Very common &ge;1/10, common &ge;1/100, &lt;1/10, uncommon &ge;1/1000 and &lt;1/100, rare &ge;1/10,000 and &lt;1/1000, very rare &lt;1/10,000, not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:1278px"><tbody><tr><td style="vertical-align:top"><p><strong>Body System</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top; width:662px"><p><strong>Side Effects</strong></p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (including cysts and polyps)</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top; width:662px"><p>secondary acute myeloid leukaemia and myelodysplastic syndrome (see section 4.4).</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and Lymphatic System Disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top; width:662px"><p>bone marrow depression leading to leucopenia, thrombocytopenia, neutropenia<sup>1</sup> and anaemia.</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top; width:662px"><p>haemolytic anaemia.</p></td></tr><tr><td style="vertical-align:top"><p>Immune System Disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top; width:662px"><p>hypersensitivity<sup>2</sup> (see Skin and Subcutaneous Tissue Disorders).</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, Thoracic and Mediastinal Disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top; width:662px"><p>interstitial lung disease and pulmonary fibrosis (including fatal reports).</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal Disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top; width:662px"><p>nausea<sup>3</sup>, vomiting<sup>3</sup> and diarrhoea; stomatitis at high dose.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top; width:662px"><p>stomatitis at conventional dose.</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary Disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top; width:662px"><p>liver disorders ranging from abnormal liver function tests to clinical manifestations such as hepatitis and jaundice.</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and Subcutaneous Tissue Disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top; width:662px"><p>alopecia at high dose.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top; width:662px"><p>alopecia at conventional dose.</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top; width:662px"><p>rash maculo-papular and pruritus (see Immune System Disorders).</p></td></tr><tr><td style="vertical-align:top"><p>Renal and Urinary Disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top; width:662px"><p>blood urea increased<sup>4</sup></p></td></tr><tr><td style="vertical-align:top"><p>Vascular Disorders<sup>5</sup></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top; width:662px"><p>deep vein thrombosis and pulmonary embolism</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top; width:662px"><p>azoospermia, amenorrhoea.</p></td></tr><tr><td style="vertical-align:top"><p>General Disorders and Administration Site Conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top; width:662px"><p>pyrexia</p></td></tr></tbody></table><p>1. Increased rate of haematological toxicities, particularly, neutropenia and thrombocytopenia, was observed in newly diagnosed elderly multiple myeloma in patients treated with melphalan in combination with lenalidomide and prednisone or thalidomide and prednisone or dexamethasone (see sections 4.4)<br />2. Allergic reactions to melphalan such as urticaria, oedema, skin rashes and anaphylactic shock have been reported uncommonly following initial or subsequent dosing, particularly after intravenous administration. Cardiac arrest has also been reported rarely in association with such events.<br />3. Gastrointestinal effects such as nausea and vomiting have been reported in up to 30% of patients receiving conventional oral doses of melphalan.<br />4. Temporary significant elevation of the blood urea has been commonly seen in the early stages of melphalan therapy in myeloma patients with renal damage.<br />5. The clinically important adverse reactions associated with the use of melphalan in combination with thalidomide and prednisone or dexamethasone and to a lesser extend melphalan with lenalidomide and prednisone include: deep vein thrombosis and pulmonary embolism (see sections 4.2 and 4.4).</p><p><u><strong>To report any side effect(s):</strong></u></p><p><strong>Saudi Arabia:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:524px"><tbody><tr><td style="vertical-align:top; width:521px"><p>&middot; The National Pharmacovigilance Centre (NPC):<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa/&nbsp;</p></td></tr></tbody></table><p><strong>-&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:529px"><tbody><tr><td style="vertical-align:top; width:526px"><p>-&nbsp;&nbsp;&nbsp;Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms and signs</u><br />Gastro-intestinal effects, including nausea, vomiting and diarrhoea are the most likely early signs of acute oral overdosage. The principal toxic effect is bone marrow suppression, leading to leucopoenia, thrombocytopenia and anaemia.</p><p><u>Treatment</u><br />General supportive measures, together with appropriate blood and platelet transfusions, should be instituted if necessary and consideration given to hospitalisation cover with anti-infective agents, and the use of haematological growth factors.</p><p>There is no specific antidote. The blood picture should be closely monitored for at least four weeks following overdosage until there is evidence of recovery.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antineoplastic and immunomodulating agents, antineoplastic agents, alkylating agents, nitrogen mustard analogues, ATC code: L01AA03.</p><p><u>Mechanism of action</u><br />Melphalan is a bifunctional alkylating anti-neoplastic agent with some immunosuppressant properties. Formation of carbonium intermediates from each of the two bis-2-chloroethyl groups enables alkylation through covalent binding with the 7-nitrogen of guanine on DNA, cross-linking two DNA strands and thereby preventing cell replication.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u><br />The absorption of oral melphalan is highly variable with respect to both the time to first appearance of the drug in plasma and peak plasma concentration.<br />In studies of the absolute bioavailability of melphalan the mean absolute bioavailability ranged from 56 to 85%.<br />Intravenous administration can be used to avoid variability in absorption associated with myeloablative treatment.<br />In a study of 18 patients administered melphalan 0.2 to 0.25 mg/kg bodyweight orally, a maximum plasma concentration (range 87 to 350 nanograms/ml) was reached within 0.5 to 2.0 h.<br />The administration of melphalan tablets immediately after food delayed the time to achieving peak plasma concentrations and reduced the area under the plasma concentration-time curves by between 39 and 54%.</p><p><u>Distribution</u><br />Melphalan displays limited penetration of the blood-brain barrier. Several investigators have sampled cerebrospinal fluid and found no measurable drug. Low concentrations (~10% of that in plasma) were observed in a single high-dose study in paediatrics.</p><p><u>Elimination</u><br />In 13 patients given oral melphalan at 0.6 mg/kg bodyweight, the plasma mean terminal elimination half-life was 90 &plusmn; 57 min with 11% of the drug being recovered in the urine over 24 h.<br />In 18 patients administered melphalan 0.2 to 0.25 mg/kg bodyweight orally, the mean elimination half-life was 1.12 &plusmn; 0.15 h.</p><p><u>Special Patient Populations</u></p><p>Renal impairment</p><p>Melphalan clearance may be decreased in renal impairment (see section 4.2 and 4.4).</p><p>Elderly<br />No correlation has been shown between age and melphalan clearance or with melphalan terminal elimination half-life (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Mutagenicity</u><br />Melphalan is mutagenic in animals.</p><p>Reproductive toxicity<br />Reproduction studies in rats treated with oral doses of 0.81-2.42 times the Maximum Recommended Human Dose (MRHD) revealed embryolethal and teratogenic effects. Congenital anomalies included those of the brain (underdevelopment, deformation, meningocele, and encephalocele), eye (anophthalmia and micropthalmos), reduction of the mandible and tail, and hepatocele (see section 4.6).</p><p>Fertility Studies<br />In mice, melphalan at clinically relevant exposure levels showed reproductive effects attributable to cytotoxicity in specific male germ cell stages and induced dominant lethal mutations and heritable translocations in post-meiotic germ cells, particularly in mid to late stage spermatids.</p><p>Females received melphalan at clinically relevant exposure levels and were then housed with an untreated male for most of their reproductive life span. A pronounced reduction in litter size occurred within the first post-treatment interval, followed by an almost complete recovery. Thereafter, a gradual decline in litter size occurred. This was simultaneous with a reduction in the proportion of productive females, a finding associated with an induced reduction in the number of small follicles (see section 4.6).</p><p>Genotoxicity<br />Melphalan has been tested for genotoxicity in a number of short-term assays, both in vitro and in vivo.<br />In mice, oral administration of melphalan at a dose of 0.81 times the MRHD increased frequencies of dominant lethal mutations, chromosomal aberrations, sister chromatic exchange, micronuclei and DNA strand breaks.<br />The observed mutations originated primarily from large deletions in the postspermatogonial cells whereas other types of mutagenic mechanisms predominated in the spermatogonial cells.<br />This in vivo data is supported by in vitro studies showing that cell culture treatment with melphalan (at concentrations ranging from 0.1 to 25 &mu;M) also induced DNA damage.<br />In addition, it induced aneuploidy and sex-linked recessive lethal mutations in Drosophila, and mutation in bacteria. It was positive with all strains in the Ames test at concentrations of 200 &mu;g/plate and above. The mutagenic activity of melphalan was increased 3-fold in the presence of liver S9 metabolising preparations, which is unexpected since melphalan is not considered to need liver activation to produce a cytotoxic effect.</p><p>Carcinogenicity<br />Melphalan is a direct-acting alkylating agent that is carcinogenic via a genotoxic mechanism, which is sufficiently supported by animal studies.<br />Development of neoplastic tumours in mice reported following oral administration of melphalan at doses of 0.10-1.63 times the MRHD; in monkeys, the carcinogenic potential was observed at a dose of 0.16 times the MRHD.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet Core</u><br />Microcrystalline cellulose<br />Crospovidone<br />Colloidal anhydrous silica<br />Magnesium stearate</p><p><u>Tablet film-coating</u><br />Hypromellose<br />Titanium Dioxide<br />Macrogol</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator 2&deg;C to 8&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alkeran Tablets are supplied in amber glass bottles of 25 or 50 tablets with a child-resistant closure.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The handling of Alkeran formulations should follow guidelines for the handling of cytotoxic drugs according to prevailing local recommendations.</p><p>Pregnant Staff should not handle cytotoxics. Protective clothing, including gloves, should be worn. Alkeran Tablets should not be divided.</p><p>Provided the outer coating of the tablet is intact, there is no risk in handling Alkeran Tablets.</p><p><u>Handling</u>:</p><ul><li>Alkeran is a hazardous drug.</li><li>&nbsp;In healthcare settings, use designated area for medication storage and restrict access to only authorized personal</li><li>To minimize the risk of dermal exposure, wear chemotherapy gloves and sleeve covers when handling Alkeran. This includes all handling activities in clinical settings, pharmacies, storerooms and home healthcare settings, including receiving, unpacking and, and storing within a facility.</li><li>&nbsp;For transportation of intact tablet within the facility, wear single chemotherapy gloves and place in double bag or in a sealed container.</li><li>The tablets should not be divided, broken or crushed. This might produce powder that can contaminate workplace surfaces.</li><li>Caution should be observed in handling broken or crushed tablets; wear double chemotherapy gloves and place in double bag or in a sealed container. Avoid direct contact with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water, rinse eyes thoroughly with sterile water, or plain water if sterile water is unavailable.</li><li>When manipulations are necessary such as compounding, crushing, cutting, or splitting; should be performed within a ventilated engineering enclosure and/ or augment the control of generated aerosols using supplementary controls such as glove bags or pill pouches that contain the hazardous drug during and after the crushing process.</li><li>&nbsp;Wear double chemotherapy gloves, protective gown and sleeve covers. Add eye/face protection and respiratory protection [N95] if compounding is done outside of the ventilated engineering control. Hair and shoe covers should be worn.</li><li>When clinically appropriate, add liquid or moist products to crushed hazardous drug product as soon as possible after crushing, to avoid the potential of subsequent aerosol dissemination.</li><li>&nbsp;For medication administration, wear single chemotherapy gloves with intact and coated tablets and double chemotherapy gloves with cut or crushed tablets. Add eye and face protection if there is the potential to contact vomit or if patient may resist or is pre-disposed to spitting out.</li><li>&nbsp;Personnel who are pregnant should avoid exposure to crushed or broken coated tablets.</li></ul><p><u>Disposal</u></p><ul><li>Wear double chemotherapy gloves and protective gown for any disposal or cleaning activity of medication contaminated waste.</li><li>Avoid creating dusts. Place in sealed bags for disposal. Use caution when closing bags as pushing waste down may force hazardous drug dusts up into the user&rsquo;s face.</li><li>For disposal of drugs and metabolites in body fluids, wear chemotherapy gloves and protective gown. Fold soft materials (sheets, hygiene care products) inward to prevent leakage and place in sealed bags.</li><li>In case of spill, limit access to area, use wet wiping method (absorbent pads for liquid spills). Place in sealed bags for disposal. Disinfection, deactivation or decontamination agents may be necessary.</li><li>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</li></ul><p>Alkeran Tablets should be destroyed in accordance with relevant local regulatory requirements concerning the disposal of cytotoxic drugs.</p><p>Adequate care should be taken in the disposal of waste material, including containers and any other contaminated material.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aspen Pharma Trading Limited
3016 Lake Drive,
Citywest Business Campus,
Dublin 24
Ireland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>